

UCB SA (UCB) - Financial and Strategic SWOT Analysis Review

<https://marketpublishers.com/r/U5C9A768F61EN.html>

Date: May 2021

Pages: 68

Price: US\$ 125.00 (Single User License)

ID: U5C9A768F61EN

Abstracts

UCB SA (UCB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

UCB SA (UCB) is a biopharmaceutical company that discovers and develops novel medicines and solutions to help treat severe diseases. It strives to develop products for the treatment of neurology and immunology related conditions. The company's marketed products include Cimzia for ankylosing spondylitis, axial spondyloarthritis, crohn's disease, psoriatic arthritis, non-radiographic axial spondyloarthritis and rheumatoid arthritis; Neupro for parkinson's disease and restless legs syndrome; Evenity for osteoporosis, and Vimpat, Keppra and Briviact for epilepsy. The company operates through subsidiaries in the US, Japan, China, Germany, Italy, Spain, France, the UK, Ireland, Belgium, Brazil, Russia, India, Mexico, Turkey and other countries. UCB is headquartered in Brussels, Belgium.

UCB SA Key Recent Developments

Mar 26,2021: UCB Convening notice annual shareholders meeting

Mar 23,2021: UCB completes institutional Eurobond offering

Mar 09,2021: Insilico's Chemistry42 AI system integrated into UCB's drug discovery programs

Feb 25,2021: UCB - sustaining growth, now and into the future

Feb 24,2021: UCB and Microsoft expand drug development partnership

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

UCB SA - Key Facts
UCB SA - Key Employees
UCB SA - Key Employee Biographies
UCB SA - Major Products and Services
UCB SA - History
UCB SA - Company Statement
UCB SA - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture

SECTION 2 – COMPANY ANALYSIS

Company Overview
UCB SA - Business Description
Product Category: Established Brands
Overview
Performance
Product Category: Immunology
Overview
Performance
Product Category: Neurology
Overview
Performance
Geographical Segment: Europe
Target Markets
Performance
Geographical Segment: International Markets
Target Markets
Performance
Geographical Segment: The US
Performance
R&D Overview
UCB SA - Corporate Strategy
UCB SA - SWOT Analysis

SWOT Analysis - Overview
UCB SA - Strengths
UCB SA - Weaknesses
UCB SA - Opportunities
UCB SA - Threats
UCB SA - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

UCB SA, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
UCB SA, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
UCB SA, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Mar 26, 2021: UCB Convening notice annual shareholders meeting
Mar 23, 2021: UCB completes institutional Eurobond offering
Mar 09, 2021: Insilico's Chemistry42 AI system integrated into UCB's drug discovery programs
Feb 25, 2021: UCB - sustaining growth, now and into the future
Feb 24, 2021: UCB and Microsoft expand drug development partnership
Feb 23, 2021: UCB and Microsoft expand collaboration to accelerate drug discovery and development
Feb 23, 2021: UCB and Microsoft expand collaboration to accelerate drug discovery and development
Feb 04, 2021: UCB Community Health Fund supports seven U.S. organizations on COVID-19 support projects
Jan 28, 2021: UCB Community Health Fund commits to 50 COVID-19 support and research projects
Jan 15, 2021: UCB announces changes on Board of Directors

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

UCB SA, Key Facts
UCB SA, Key Employees
UCB SA, Key Employee Biographies
UCB SA, Major Products and Services
UCB SA, History
UCB SA, Subsidiaries
UCB SA, Joint Venture
UCB SA, Key Competitors
UCB SA, Ratios based on current share price
UCB SA, Annual Ratios
UCB SA, Annual Ratios (Cont...1)
UCB SA, Annual Ratios (Cont...2)
UCB SA, Interim Ratios
UCB SA, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
UCB SA, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
UCB SA, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

UCB SA, Performance Chart (2016 - 2020)

UCB SA, Ratio Charts

UCB SA, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

UCB SA, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021

I would like to order

Product name: UCB SA (UCB) - Financial and Strategic SWOT Analysis Review

Product link: <https://marketpublishers.com/r/U5C9A768F61EN.html>

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/U5C9A768F61EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970